natgillin/translations-raw huggingface dataset:
Care must here be taken to ensure that each of the subunits is formulated in accordance with the above-stated process. 
Pritom treba paziti na to, da se svaka od navedenih podjedinica formulira prema prethodno navedenom postupku.
is selected from the group consisting of C=O and CH2; 
G, je odabran iz skupine koja sadrži N 1 CR;;
Again, to this regard the control means can monitor the current status of the beverage production device. 
Sustav za kontrolu može i u ovom slučaju pratiti trenutno stanje naprave za proizvodnju napitaka.
wherein said stabilizing agent is trehalose at a concentration of about 1.5% to about 20% w/v; 
navedeno sredstvo za dopunjavanje je 4.0 % w/v manitol; i navedeni stabilizator je 2.0 % w/v saharoza;
In certain embodiments, the present invention provides a pharmaceutical composition for use in the treatment of ocular lubrication deficiency or symptoms associated therewith for topical administration to an ocular surface of an individual in need a pharmaceutically effective concentration of a PRG4 inducing compound, as defined in the appended claims, an optional mucoadhesive agent, and PRG4 suspended in an ophthalmically acceptable balanced salt solution, and in combination with one or more ophthalmically acceptable agents. 
HR P20150097 T1 PATENTNI ZAHTJEVI Farmaceutski oblik za uporabu u liječenju vodene ili isparavajuće bolesti suhog oka, stanja koja su povezana s ili uzrokuju vodenu ili isparavajuću bolest suhog oka, ili s njima povezanih simptoma, u pojedinca, oblik je prikladan za topikalnu primjenu na površinu oka, sadrži terapijski učinkovitu koncentraciju PRG4 suspendiranog u oftalmički prikladnoj uravnoteženoj fiziološkoj otopini.
Four major areas of the brain are involved as primary pathways for dopamine. 
Četiri su glavna područja mozga uključena kao primarni putevi za dopamin.
The composition according to claim 1, wherein the pH value is within the range of from 4.5 to 5.5, in particular before and after autoclaving. 
Sastav prema bilo kojem od prethodnih zahtjeva, naznačen time što je pH vrijednost unutar raspona od 4,5 do 5,5, posebice prije i poslije autoklaviranja.
The wash fractions were collected and pooled with the retentate fraction (final volume 200-250 mL). 
Frakcije od ispiranja bile su sakupljene te združene sa zaostalom frakcijom (konačan voluman 200-250 mL).
The compound for use according to any one of the preceding claims for preventing or inhibiting vascularization in an inflammatory condition, particularly wherein the inflammatory condition is selected from the group consisting of arthritis, inflammatory bowel diseases, eczema, and neurodermatitis. 
Spoj namijenjen upotrebi u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što je namijenjen sprječavanju 1li inhibiranju vaskulariziranja u upalnom stanju, osobito kada se upalno stanje bira iz skupine koju čine artritis, upalne bolesti crijeva, egzem, te neurodermatitis.
a disintegrant selected from the group croscarmellose sodium, sodium starch glycolate, crosslinked polyvinylpyrrolidone and mixtures thereof. 
(c) razgrađivač odabran iz skupine kroskarameloza natrija, natrij škrob glikolata, međupovezanog polivinilpirolidona i njihovih smjesa.
In general it can be said, the shorter the wavelength the higher the rate at which sunstruck flavour is formed. 
Općenito se može reći, što je manja valna duljina, veća je brzina kojom se stvara užegla aroma.
minimising loss of expression of virulence factors in growth in industrial culture, or 
(ii) minimaliziranja gubitaka eksprimiranja čimbenika virulentnosti prilikom rasta u industrijskoj kulturi, ili
A method of preparation of docosahexaenoic acid ester according to claim 1 or 2 by transesterification of docosahexaenoic acid ethyl ester with the alcohol chosen among the group consisting of panthenol, isosorbide and isosorbide mononitrate. 
Metoda priprave estera dokosaheksanske kiseline prema patentnom zahtjevu 1 ili 2, naznačena time da obuhvaća transesterifikaciju etilnog estera dokosaheksanske kiseline s alkoholom odabranim iz sljedeće skupine: pantenol, izosorbid te izosorbid-mononitrat,
The pharmaceutical composition for use according to any of the claims 6 to 10, wherein the composition further comprises 0.1 µg to 10 µg lixisenatide per U insulin glargine. 
Vodena formulacija namijenjena upotrebi u skladu s patentnim zahtjevom 21, naznačena time što navedeni farmaceutski pripravak dodatno sadrži 0,1 µg do 10 µg liksisenatida po jedinici inzulin glargina.
the antibody does not compete for AXL binding with the ligand Growth Arrest-Specific 6 (Gas6) and 
se protutijelo ne natječe s ligandom Gas6 – ligandom specifične regulacije rasta 6 (engl. Growth Arrest-Specific 6) i
Transdermal therapeutic system according to claim 8 wherein the dosage unit has 0.525 or 1.05 mg mg Gestodene per dosage unit together with 0.55 mg Ethinylestradiol in a polyisobutylene-containing matrix with a size of 11 cm2. 
Transdermalni terapijski sustav prema zahtjevu 8 naznačen time da jedinica doziranja ima 0.525 ili 1.05 mg Crestodena po jedinici doziranja zajedno s 0.55 mg Etinilestradiola u matrici koja sadrži poliizobutilen s veličinom od 11 cm".
a CDRH1 sequence corresponding to amino acid residues 31 to 35 (SYWMN) of SEQ ID NO: 15, wherein one of said amino acid residues is optionally a different amino acid residue; 
(i) CDRHI sekvencu koja odgovara aminokiselinskim ostacima 31 do 35 (SYWMN) iz SEK ID BR: 15, gdje jedan od spomenutih aminokiselinskih ostataka je po izboru različit aminokiselinski ostatak;
pyrimidinyl, said pyrimidinyl being unsubstituted or substituted with one, two or three substituents independently selected from halogen and C1-6alkyl; 
pirimidinil, pri čemu je navedeni pirimidinil nesupstituiran ili supstituiran s jednim, dva ili tri supstituenta neovisno odabrana iz halogena i C1−6alkila;
The method of any of claim 1 to 10, 17, and 18, wherein the rf allele is linked to and/or associated with the SSR markers consisting of a PCR fragment with an apparent molecular weight of 240.8 (+/- 0.4) bp resulting from a PCR reaction with the primer pair SEQ ID NO: 19 and 20. 
Postupak prema bilo kojem od zahtjeva 1 do 7, 14 i 15 naznačen time da rf alel is vezan sa i/ili udružen sa SSR markerima koji se sastoje od PCR fragmenta sa očitom molekularnom težinom od 240,8 (+/- 0.4) bp koja proizlazi iz PCR reakcije sa početnicama koje imaju sekvence navedene kao SEQ ID NOs: 191 20.
wherein G1 represents halogen, or a salt of said compound, with 2-(tert-butoxy)ethanol in the presence of a base at a temperature from 25 to 140° C. 
I-1 gdje G' predstavlja halogen, ili soli navedenog spoja, S 2-(tert-butoksijetanolom u prisutnosti lužine na temperaturi od 25 do 140*C.
or a pharmaceutically acceptable salt, stereoisomer, or N-oxide thereof. 
O-NH ili farmaceutski prihvatljiva sol, stereoizomer ili N-oksid takvoga spoja.
Removing mechanically all soft tissue in pulpa and all excavation of root canal (→ apical opening minus 1-2 mm) 
Uklanjanje mehanički cijelog mekog tkiva u pulpi 1 u kanalu korijena (-gornji otvor minus 1-2 mm)
Use according to any of the preceding claims, wherein said composition comprises penetration enhancers, sedimentation retarders, chelating agents, antioxidants, silicates, aroma substances, wetting agents, lanolin derivates, light stabilizers and/or antibacterial substances. 
Upotreba prema bilo kojem od prethodnih zahtjeva, naznačena time, da navedeni pripravak sadrži pojačivače penetracije, usporivače sedimentacije, kelirajuće agense, antioksidanse, silikate, arome, ovlaživače, derivate lanolina, svjetlosne stabilizatore i/ili antibakterijske supstance.
The pharmaceutical composition of claim 22, wherein the PEG is covalently attached to the surface of the particles or tethered to the surface of the particles by hydrophobic or charge interactions. 
Postupak prema bilo kojem od zahtjeva 1-5 i 8-11 ili farmaceutski sastav prema bilo kojem od zahtjeva 6-11, pri čemu je polietilen glikol kovalentno pripojen na površinu čestica ili vezan na površinu čestica hidrofobnim ili nabojnim interakcijama.
at least one light chain variable region, said light chain variable region comprising at least one member from the group consisting of: 
Izolirano IL-23p19 antitijelo, koje sadrži: najmanje jednu varijabilnu regiju lakog lanca, spomenutu varijabilnu regiju lakog lanca koja sadrži:
Assay for determining mature adrenomedullin (1-52-amide) and/ or adrenomedullin-Gly in a sample comprising two binders that are selected from the group comprising an anti-adrenomedullin antibody and an anti-ADM antibody fragment binding to ADM and that bind to two different regions within the region of mature adrenomedullin (1-52-amide) and/ or adrenomedullin-Gly, that is amino acid 21-52-amide SEQ ID No. 
Test za određivanje zrelog adrenomedulina (amida 1-52) i/ili adrenomedulina-Gly u uzorku, naznačen time što sadrži dva liganda koje se bira iz skupine koju čine protutijelo protiv adrenomedulina i fragment protutijela protiv ADM koji se veže na ADM i veže se na dva različita područja unutar područja zrelog adrenomeđulina (amida 1-52) iili adrenomedulina-Gly, koji je amid slijed aminokiselina 21-52 (SEQ ID No.
The pharmaceutical composition of any preceding claim, wherein the intranasal formulation is in the form of a nasal spray or drops. 
Farmaceutski pripravak u skladu s patentnim zahtjevom 1, naznačen time što je navedeni pripravak formuliran kao tekuća formulacija u obliku nazalnog spreja ili nazalnih kapi.
After stirring at room temperature for 1 hour, the resulting solution is added dropwise to a stirred solution of 1-bromomethyl-4-methanesulfonyl-3-trifluoromethyl-benzene (23.9 g, 75.4 mmol) and stirred for 18 hours. 
Nakon miješanja 1 sat pri sobnoj temperaturi, dobivenu otopinu se doda, kap po kap, u miješanu otopinu 1-brom-metil-4-metansulfonil-3-trifluormetil-benzena (23,9 g, 75,4 mmolova) i miješa se 18 sati.
The bag-in-container according to any of the preceding claims, wherein more than one vent (3) is distributed around the lip of the bag-in-container's mouth (5). 
Posuda s vrećicom unutar nje prema bilo kojom prethodnom patentnom zahtjevu, naznačena time da je više od jedan otvor (3) raspoređen oko ruba otvora posude s vrećicom unutar nje.
An immunoconjugate comprising a monoclonal antibody or fragment thereof that binds to CD22 covalently attached to a cytotoxic agent, wherein the antibody comprises a heavy chain variable domain having the amino acid sequence of SEQ ID NO:16, and a light chain variable domain having the amino acid sequence of SEQ ID NO:18. 
PATENTNI ZAHTJEVI Imunokonjugat koji sadrži protutijelo ili njegov fragment koji se veže na antigen, naznačen time, da je kovalentno priključen na citotoksični agens, pri čemu je to protutijelo ili njegov fragment koje/i se veže na antigen, monoklonalno protutijelo ili njegov fragment koji se veže na antigen, koje/i se veže na CD22 i sadrži varijabilnu domenu jakog lanca, koja ima aminokiselinsku sekvencu od SEQ
The method of aspect 5, wherein the MASP-2 inhibitory agent is a MASP-2 monoclonal antibody, or fragment thereof that specifically binds to a portion of SEQ ID NO:5. 
Pripravak namijenjen upotrebi u skladu s patentnim zahtjevom 2, naznačen time što je sredstvo za inhibiranje MASP-2 monoklonsko protutijelo protiv MASP-2, ili njegov fragment, koje se specifično veže na dio SEQ ID NO:5.
providing at least one dermal papilla (DP) from at least one mammal hair follicle, 
(a) osiguravanja barem jedne dermalne papile (DP) iz barem jedne folikule kose sisavaca,
A macrophage migration inhibitory factor inhibitor comprising a benzopyran derivative represented by the following general formula, or a salt thereof, wherein R1 represents an optionally substituted C1-6 alkyl group; one of R2 and R3 represents a hydrogen atom; and the other of R2 and R3 represents a hydrogen atom, an optionally substituted amino group, an optionally substituted acylamino group, an optionally substituted carbamoyl group or an optionally substituted aryl group. 
O R o=s=0 R jedan od R2 i R3 predstavlja atom vodika, a drugi od R, i Rz predstavlja atom vodika, po izboru supstituiranu amino skupinu, po izboru supstituiranu acilamino skupinu, po izboru supstituiranu karbamoilnu skupinu ili po izboru supstituiranu arilnu skupinu.
A pharmaceutical composition comprising an effective amount of a compound of claim 1 or claim 20 or a pharmaceutically acceptable salt thereof for use in the treatment of pain, urinary incontinence, an ulcer, irritable-bowel syndrome or inflammatory-bowel disease. 
Farmaceutski pripravak naznačen time da sadrži učinkovitu količinu spoja prema zahtjevu 1 ili zahtjevu 20 ili njegovu farmaceutski prihvatljivu sol za uporabu kod liječenja boli, uriname inkontinencije, čira, sindroma iritabilnog crijeva ili upalnog poremećaja crijeva.
Ashes 3.5 A cocoa-derived material comprising a soluble cocoa powder and a cocoa extract, whereby said cocoa extract comprises polyphenols in an amount of more than 25% by weight based on the extract, and whereby said soluble cocoa powder has a solubility in an aqueous solvent at a temperature of 20°C of at least 70%, wherein the weight ratio of soluble cocoa powder to cocoa extract in said material is comprised between 3:1 and 1:3, and wherein said cocoa-derived material is a syrup or is a powder, and wherein said material, when provided as a syrup has an ORAC value of between 50 and 250 µmol TE/g syrup, and when provided as powder has an ORAC value of between 10 and 10000 µmol TE/g powder. 
Tvar dobivena iz kakaa koja sadrži topljivi prašak kakaa i ekstrakt kakaa, naznačena time, da dotični ekstrakt kakaa sadrži maseni udjel polifenola veći od 25 % mase ekstrakta, a topljivost dotičnog topljivog praška kakaa u vodenom otapalu na temperaturi od 20 *C iznosi najmanje 70 %, pri čemu je omjer mase topljivog praška kakaa prema masi ekstrakta kakaa u dotičnoj tvari u rasponu omjera od 3:1 do 1:3, pri čemu je navedena tvar dobivena iz kakaa u obliku sirupa ili u obliku praška, pri čemu navedena tvar, kada se nalazi u obliku sirupa, ima vrijednost prema ljestvici ORAC u rasponu od 50 do 250 Pmol TE/g sirupa, a kada se nalazi u obliku praška ima vrijednost prema ljestvici ORAC u rasponu od 10 do 10.000 Pmol TE/g praška.
The sewing or looping head according to claim 4, wherein said needle can move along the corresponding actuation path on a first actuation plane that is substantially perpendicular to the advancement direction of the article being sewn and can engage the article cyclically; said crochet being movable along the corresponding actuation path on a second actuation plane that is substantially perpendicular to said first actuation plane; said cutting plane being substantially parallel to said first actuation plane. 
Glava za šivanje ili pravljenje petlji prema bilo kojem od prethodnih patentnih zahtjeva, naznačena time da se navedena igla (2) može pomicati duž odgovarajuće radne putanje na prvoj radnoj ravnini koja je u biti okomita na smjer napredovanja (40) proizvoda koji se šivani 1 može zahvatiti proizvod ciklično; navedena kuka (3) može se pomicati duž odgovarajuće radne putanje na drugoj radnoj ravnini koja je uglavnom okomita na navedenu prvu radnu ravninu; navedena rezna ravnina (31) je u biti paralelna s navedenom prvom radnom ravninom.
The composition or vaccine of any one of claims 1-8 for use in a method of vaccinating an animal, said method comprising at least one administration of the composition or vector. 
Sastav ili cjepivo za uporabu prema bilo kojem od zahtjeva 1-8, naznačen/o time, da nadalje obuhvaća farmaceutski ili veterinarski prihvatljiv/o nosač, pomoćno sredstvo, prenositelj 1li kemijski dodatak.
A composition comprising the isolated IL-23p19 antibody according to claim 9 and at least one pharmaceutically acceptable carrier or diluent. 
Pripravak koji sadrži najmanje jedno izolirano IL-23p19 antitijelo prema patentnim zahtjevima 1-5 i najmanje jedan farmaceutski prihvatljiv nosač 1li razrjeđivač.
Compounds of the Formula VIII may be prepared using conventional methods well known in the art. 
Spojevi prikazani Formulom VIII mogu se pripraviti konvencionalnim postupcima poznatim u struci.
A compound as claimed in claim 1, wherein Y is and R2 is alkyl, heterocyclyl, heterocyclylalkyl, carbocyclylalkyl; wherein said alkyl is methyl or C2-C4 alkyl, and wherein said alkyl is optionally substituted with at least one hydroxy, alkoxy, amino, alkylamino, diakylamino, or fluoro substituent; wherein said heterocyclyl is optionally a 4- to 6-membered oxygen- or nitrogen-containing heterocyclyl; wherein said heterocyclylalkyl is optionally C1-C3 alkylene, or a 4- to 6-membered oxygen- or nitrogen-containing heterocyclyl; and wherein said carbocyclylalkyl optionally consists of a C1-C3 alkylene or a 3- to 7-membered carbocyclyl. 
Spoj sukladno patentnom zahtjevu 1, pri tome je Y [image] i R2 je alkil, heterociklil, heterociklilalkil, karbociklilalkil; pri tome je navedeni alkil metil ili C2-C4 alkil i pri tome je navedeni alkil opcijski supstituiran s najmanje jednim hidroksi, alkoksi, amino, alkilamino, diakilamino ili fluoro supstituentom; pri tome je navedeni heterociklil opcijski jedan 4- do 6-člani heterociklil koji sadrži kisik ili dušik; pri tome je navedeni heterociklilalkil opcijski C1-C3 alkilen, ili jedan 4- do 6-člani heterociklil koji sadrži kisik ili dušik; i pri čemu se navedeni karbociklilalkil opcijski sastoji od C1-C3 alkilena ili jednog 3- do 7-članog karbociklila.
A kit for mechanically cleaning and/or disinfecting medical and/or surgical instruments and/or devices, the kit containing a first component containing at least 15 wt. % alkanolamine and at least 10 wt. % complexing agent, and a second component containing at least one enzyme; and a method of cleaning such instruments and devices using the components of the kit. 
HR P20190316 T1 PATENTNI ZAHTJEVI Pribor za strojno čišćenje i/ili dezinfekciju medicinskih i/ili kirurških instrumenata i/ili uređaja, naznačen time što sadrži: a) prvu komponentu koja sadrži najmanje 15% mase alkanolamina 1 najmanje 10% mase kompleksirajućeg sredstva; b) drugu komponentu koja sadrži najmanje jedan enzim.
The use of claim 35, wherein the nebulizer is configured to administer the aerosol to the lung in less than about 10 minutes, preferably in less than about 5 minutes, more preferred in less than about 3 minutes, even more preferred in less than about 2 minutes. 
37. Uporaba iz patentnog zahtjeva 35, pri čemu se nebulizator konfigurira primijeniti aerosol na pluća za manje od oko 10 minuta, preporučljivo za manje od oko 5 minuta, još preporučljivije za manje od oko 3 minute, još preporučljivije za manje od oko 2 minute.
The method of preparing a polymer hydrogel of the present invention comprises the step of cross-linking an aqueous solution comprising a hydrophilic polymer with a polycarboxylic acid, thereby producing the polymer hydrogel. 
(b) zagrijavanje otopine radi uklanjanja vode i poprečnog povezivanja karboksimetilceluloze s limunskom kiselinom, pri čime se formira polimerni hidrogel; gdje navedeni polimerni hidrogel ima udio bubrenja u destiliranoj vodi od najmanje 50.
The composition of any preceding claim, wherein the first polynucleotide encodes an FeLV ENV polypeptide having an amino acid sequence as set forth in SEQ ID NO:2 or 4, and wherein the second polynucleotide encodes an FeLV GAG/PRO polypeptide having an amino acid sequence as set forth in SEQ ID NO:12. 
Sastav prema bilo kojem od prethodnih zahtjeva, naznačen time, da prvi polinukleotid kodira ENV polipeptid za FeLV, koji ima aminokiselinsku sekvencu prikazanu u SEQ ID NO: 2 ili 4, te time, da drugi polinukleotid kodira GAG/PRO polipeptid za FeLV, koji ima aminokiselinsku sekvencu prikazanu u SEQ ID NO: 12.
The crimped end 58, at the fuel end, preferably abuts the rear end of the fuel element to provide for conductive heat transfer. 
Naborani kraj 58, na gorivom kraju, poželjno dodiruje zadnji kraj gorivog elementa 10 da se osigura provodljiv prijenos topline.
An animal was considered as fully protected by treatment if a thrombus did not occlude the vessel during the period of study (60 min after FeCl3 continue patch application). 
Zivotinja se smatra potpuno zaštićena liječenjem ako tromb ne začepi krvnu žilu tijekom perioda proučavanja (60 min nakon trajne aplikacije FeCl; flastera).
A reactor according to claim 5, characterized in that when the hinging means are provided in only one of the said zones, rigid fastening means are provided in the second zone thereof for the connection of the flexible elements to the load-bearing structure, or alternatively to the oscillating mass. 
Reaktor u skladu s patentnim zahtjevom 3, naznačen time što kada su šarke dodane u samo jedno od navedenih područja, rigidni pričvršćivači su dodani u njegovo drugi dio za povezivanje fleksibilnih elemenata s nosivom strukturom, ili pak s oscilirajućom masom.
ET-743 purity evaluation after 6 months storage at 5° C. FIG. 
Procjena čistoće ET-743 poslije 6 mjeseci čuvanja na 5*C.
stereoisomeric form thereof and/or tautomeric form thereof and/or pharmaceutically acceptable salt thereof. 
Lje O, S ili NH; ili njihovi stereoizomerni i/ili tautomerni oblici i/ili njihove farmaceutski prihvatljive soli.
A method for determining if a CHK-1 inhibitor is inhibiting its molecular target CHK-1, the method comprising: 
Postupak za određivanje da li CHK-I inhibitor inhibira svoj molekularni ciljani CHK-1, naznačen time da se postupak sastoji od:
an autoimmune disease wherein said autoimmune disease is bullous skin disorder; 
Spoj ili sol prema zahtjevu 50 naznačen time da navedena autoimuna bolest je bulozni kožni poremećaj.
reacting at least a portion of the sucrose contained in the first educt composition with at least a portion of the phosphate contained in the first educt composition with catalysis by means of the sucrose phosphorylase, wherein there is obtained a first product composition which comprises fructose and glucose 1-phosphate; 
reagiranje barem dijela saharoze sadržane u prvom pripravku edukta sa najmanje dijelom fosfata sadržanog u prvom pripravku edukta s katalizom pomoću saharoze fosforilaze, pri čemu je dobiven prvi pripravak proizvoda koji sadrži fruktozu i glukozu 1-fosfat;
Therapeutic cells for use according to one of the preceding claims, said treatment further comprising applying the at least one therapeutic cell to the upper third of the animal's nasal cavity in a physiologically effective amount to provide therapeutic action comprising replacement of lost and/or dying cells in the damaged central nervous system. 
Terapijske stanice namijenjene upotrebi u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačene time što se navedeno liječenje dodatno sastoji u primjeni najmanje jedne terapijske stanice u gornju trećinu nosne šupljine životinje u fiziološki djelotvornoj količini kako bi se osiguralo terapijsko djelovanje, koje se sastoji u zamjeni izgubljenih i/ili umiručih stanica u oštećenom središnjom živčanom sustavu.
as well as pharmaceutically acceptable salts and polymorphs of said compounds and hydrates of the compounds of formula I and of their salts. 
XjeCHiliN, kao i farmaceutski prihvatljive soli i polimorfi navedenih spojeva i hidrata spojeva formule I i njihovih soli i manitol kao stabilizator.
A hand held medicine dosing and dispensing device according to Claims 23 and 24 wherein the display and the data input device are provided in the form of a touch-sensitive screen. 
Ručni uređaj za doziranje 1 izdavanje lijeka prema zahtjevima 23 i 24 naznačen time da su zaslon i uređaj za unos podataka predviđeni u obliku zaslona osjetljivog na dodir.
-[4-(Amino-phenyl-methyl)-cyclohexyloxy]-7-chloro-2H-isoquinolin-1-one, and their stereoisomeric and/or tautomeric forms and/or their pharmaceutically acceptable salts thereof. 
-[4-(amino-fenil-metil)-cikloheksiloksi]-7-kloro-2H-izokinolin-1-on, i njihovi stereoizomerni i/ili tautomerni oblici i/ili njihove farmaceutski prihvatljive soli.
an amount of an aqueous base sufficient to provide a final pH of the composition in the range of about 2 to about 6. 
dovoljnu količinu vodene baze da se dobije konačni pH pripravka u rasponu od 2 do 6.